BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

EVA Pharma and CHICO Pharmaceutical unite to localise oncology API production for the Middle East and Africa

June 24, 2025 | News | By Ankit Kankar | ankit.kankar@mmactiv.com

Strategic MoU signed at CPHI China 2025 aims to strengthen regional cancer care and pharmaceutical supply chains through technology transfer and local synthesis of high-potency oncology ingredients



Bridging China and the Middle East to Strengthen Regional Supply chains and Impact Millions of Cancer Patients

On the sidelines of CPHI China 2025, EVA Pharma, one of the leading pharmaceutical companies driving healthcare innovation and access across the Middle East and Africa, and CHICO Pharmaceutical, a high-tech enterprise specializing in CDMO services for pharmaceutical raw materials and the production of high-end pharmaceutical intermediates, signed a landmark Memorandum of Understanding (MoU) to establish a collaboration focused on the technology transfer and localized synthesis of oncology Active Pharmaceutical Ingredients (APIs).

The agreement covers the tech transfer of 10 advanced small-molecule anti-neoplastic and high-potency APIs, with the aim of enhancing local and regional manufacturing capabilities for critical oncology treatments at EVA Pharma's EU-GMP certified high-containment facility.

"We are committed to go above and beyond to relieve the health and economic burden of cancer across the Middle East & Africa. This is the role we proudly uphold for the region." Said Riad Armanious, CEO of EVA Pharma. "Oncology APIs are critical to the pharmaceutical supply chain, and that's why we are determined to reprioritize resources to invest in their sustainable, high-quality production. We're proud to explore this opportunity with CHICO Pharmaceutical, whose expertise strengthens our shared vision for more accessible cancer care".

This agreement reflects our shared commitment to strengthening cancer care by technology transfer to production high-quality oncology APIs," said **Mr. Xueping Wu**, **Chief Executive of Anqing CHICO Pharmaceutical**. "We are proud to

work alongside EVA Pharma to build a more resilient and sustainable pharmaceutical supply chain in the Middle East and Africa—ultimately improving access to life-saving treatments for millions of patients across the region."

The production of high-quality, anticancer components is essential to advancing modern therapies for one of the world's most common diseases. **EVA Pharma's EU-GMP-certified high-containment facility** is designed to meet the world's most rigorous standards, ensuring the safety, efficacy, and consistency of high-potency oncology ingredients.

CHICO Pharmaceutical brings decades of expertise in advanced chemical synthesis and oncology innovation. Through this collaboration, EVA Pharma will leverage their combined capabilities to establish localized production and expand access to critical cancer treatments across the region.